KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCA Healthcare (HCA) Long-Term Investments (2016 - 2025)

HCA Healthcare (HCA) has disclosed Long-Term Investments for 16 consecutive years, with $654.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Long-Term Investments fell 7.23% to $654.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $654.0 million, a 7.23% decrease, with the full-year FY2024 number at $662.0 million, up 38.78% from a year prior.
  • Long-Term Investments was $654.0 million for Q3 2025 at HCA Healthcare, down from $662.0 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $739.0 million in Q3 2023 to a low of $381.0 million in Q4 2022.
  • A 5-year average of $512.3 million and a median of $442.5 million in 2022 define the central range for Long-Term Investments.
  • Peak YoY movement for Long-Term Investments: dropped 13.01% in 2022, then surged 66.44% in 2023.
  • HCA Healthcare's Long-Term Investments stood at $438.0 million in 2021, then fell by 13.01% to $381.0 million in 2022, then increased by 25.2% to $477.0 million in 2023, then skyrocketed by 38.78% to $662.0 million in 2024, then fell by 1.21% to $654.0 million in 2025.
  • Per Business Quant, the three most recent readings for HCA's Long-Term Investments are $654.0 million (Q3 2025), $662.0 million (Q4 2024), and $705.0 million (Q3 2024).